A clinical stage business, developing theranostics for rare cancers. A Centocor spinoff, we’re rooted in a decade of innovative collaborative research, a robust pipeline and an outstanding scientific network. In clinical development: EBTATE (177Lu-EBTATE) A long lived radiotherapeutic for gastroenteropancreatic neuroendocrine and Hürthle cell thyroid tumors (under license from the NIH) Early human testing showed EBTATE is safe and more effective than competitors. US trials begin in Q4 2021 at Memorial Sloan Kettering Cancer Center. EBRGD (177Lu-EBRGD) A long-lived radiotherapeutic for αvβ3 expressing tumors. We're targeting glioblastoma multiforme and non-small cell lung cancer. (under license from the NIH). Trials planned in 2022. FGA (18F-fluoroglucaric acid) A PET radiodiagnostic targeting histones released during necrosis and cell death. Focused on tumor response to chemotherapy of brain and lung cancers. TDURA (99mTc-duramycin) A SPECT radiodiagnostic targeting phosphatidylethanolamine, exposed on cell surfaces during cell death. Focused on very early visualization of tumor death during chemotherapy, distinguishing responders from non-responders in one day. Phase 0/I trials in colorectal tumor response to therapy underway at the University of Antwerp.
View Top Employees from Molecular Targeting Technologies,IncWebsite | http://www.mtarget.com |
Revenue | $811000 |
Employees | 6 (4 on RocketReach) |
Founded | 2011 |
Address | 833 Lincoln Ave Unit 9, West Chester, Pennsylvania 19380, US |
Phone | (610) 738-7938 |
Technologies |
JavaScript,
HTML,
Nginx
+3 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Business Services General, Biotechnology, Business Services, Science and Engineering |
Competitors | Cancer Prevention Pharmaceuticals, Inc, Cellectar Biosciences, Inc., ImaginAb, Navidea Biopharmaceuticals Limited, Patrys Limited |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 54171 Companies, NAICS Code 5417 Companies, NAICS Code 541 Companies, NAICS Code 541713 Companies |
Looking for a particular Molecular Targeting Technologies,Inc employee's phone or email?
The Molecular Targeting Technologies,Inc annual revenue was $811000 in 2024.
Jianwei Xu is the Chief Business Officer of Molecular Targeting Technologies,Inc.
4 people are employed at Molecular Targeting Technologies,Inc.
Molecular Targeting Technologies,Inc is based in West Chester, Pennsylvania.
The NAICS codes for Molecular Targeting Technologies,Inc are [54, 54171, 5417, 541, 541713].
The SIC codes for Molecular Targeting Technologies,Inc are [873, 87].